EVT EXECUTE EVT INNOVATE CAREER INVEST ABOUT DE EN Stock information INVEST STOCK INFORMATION STOCK PRICE AND CHART SHAREHOLDER STRUCTURE FINANCIAL ANALYSTS DIVIDEND NEWS FINANCIAL PUBLICATIONS IR EVENTS ANNUAL GENERAL MEETING CORPORATE GOVERNANCE Be invited to scroll down for detailed information regarding the Evotec AG share, ranging from basic share data to our dividend policy. BASIC SHARE DATA Security identification numbers Frankfurt Stock Exchange (ordinary bearer shares) ISIN: DE0005664809 OTC Markets, OTCBB (American Depositary Shares, ADSs) CUSIP: 30050E105 ISIN: US30050E1055 Ticker symbol Frankfurt Stock Exchange: EVT OTC Markets, OTCBB: EVTCY Bloomberg Xetra: EVT GY Equity Bloomberg OTC Markets, OTCBB: EVTCY US Equity Reuters Xetra: EVTG.DE Stock exchange Frankfurt Stock Exchange OTC Markets, OTCBB Segment Prime Standard Index TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX Designated sponsor ODDO SEYDLER BANK AG Number of shares issued 147,547,269 ordinary bearer shares Nominal capital € 147,547,269 SHARE PRICE SUMMARY 2017 (XETRA) High (04 Oct) € 22.50 Low (09 Feb) € 6.91 Opening Price € 7.46 Closing Price € 13.50 Weighted average number of shares outstanding 145,009,742 Total number of shares outstanding as at 31 Dec 147,532,681 Average daily trading volume (all exchanges) 1,662,539 shares Market capitalisation as at 31 Dec € 1,991.7 m Earnings per share (diluted/basic) € 0.16/€ 0.17 Dividend per share € 0.00 Initial public offering information* Segment: Neuer Markt, Frankfurt Stock Exchange Offering structure: Public Offering in Germany, Private placement outside Germany, Rule 144A offering in the USA Offer shares: 4,927,500 Offer shares each with an imputed share in the capital stock of € 1.00 per share, of which: 4,100,000 New shares issued from a capital increase 182,500 Shares sold by the selling shareholder 645,00 Over-Allotment option from a capital increase Global coordinators: UBS Warburg AG, Deutsche Bank AG Further managers: SG Investment Banking, Sal. Oppenheim, Hamburger Sparkasse Bookbuilding period: 02 November 1999 - 08 November 1999 Offering price: € 13.00 Listing: 10 November 1999 Opening price: € 24.00 Subscribed capital: € 12,078,000 *All data not adjusted for stock split of 18 August 2000 STOCK PRICE & CHART SHAREHOLDER STRUCTURE As of 30 April 2018, the number of total voting rights amounts to 147,547,269. Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec AG whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de. MOST RECENT VOTING RIGHTS ANNOUNCEMENTS Date of the notification Name of the person/company subject to the notification obligation 18 April 2018 JPMorgan Chase 17 April 2018 JPMorgan Chase 18 January 2018 Deutsche Asset Management Investment GmbH Four major shareholders, Novo Holdings A/S, ROI Verwaltungsgesellschaft mbH/Roland Oetker and Allianz Global Investors ("AGI"), and Deutsche Asset Management Investment GmbH ("DAMI") have exceeded the threshold of 5%. The free float according to the definition of the Frankfurt Stock Exchange is approx. 65% according to our estimates (Evotec: 01/2018). Shareholder structure (in %) FINANCIAL ANALYSTS Overview of analysts covering the Evotec share Bankhaus Lampe Volker Braun Joh. Berenberg, Gossler & Co. KG Klara H. Fernandes Deutsche Bank Falko Friedrichs EQUI.TS GmbH Thomas Schießle goetzpartners securities Limited Martin Brunninger Kempen & Co. N.V. Anastasia Karpova ODDO BHF Igor Kim Rx Securities Dr Samir Devani Important note: Evotec is monitored and assessed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Evotec’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Evotec or its management. Evotec does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Evotec has no obligation to update or supplement the above information and makes no representation or warranty as to the accuracy and completeness of this list. Copies of the research reports of the above-named analysts must be obtained directly from the analysts or their employers. Evotec is not able to publish the research reports due to legal considerations. DIVIDEND Payment of dividends is dependent upon Evotec AG’s financial situation and liquidity requirements, the general market conditions and statutory, tax and regulatory requirements. Evotec currently intends to retain any potential future profits and reinvest them in the Company’s further growth strategy. CONTACT US Gabriele Hansen VP, Corporate Communications & Investor Relations T +49 40 560 81 255 F +49 40 560 81 333 investorrelations@evotec.com vCard Katja Werner Investor Relations Associate T +49 40 560 81 210 F +49 40 560 81 333 investorrelations@evotec.com vCard Tuesday, May 1st 2018 Previous Next 2 °C Alderley Park (Cyprotex) Imprint Privacy Policy Legal notice T&Cs RSS RSS Twitter LinkedIn EVOTEC @EvotecAG RT @AlderleyPark: We’re delighted to be hosting @OfficialUoM students today who are hearing about career opportunities in #lifesciences and… 12:30 PM - 27 APRIL 2018